Disclosed herein is the use of a compound of formula (I) in the preparation of a medicament for treating a disease or disorder responsive to improvements in cognitive function and for treating cognitive impairment selected from autism, dyslexia, attention deficit hyperactivity disorder, obsessive compulsive disorders, psychosis, Tourettes syndrome, Mild Cognitive Impairment (MCI), and disorders of learning in children, adolescents and adults, Age Associated Memory Impairment, Age Associated Cognitive Decline with the proviso that said treatment excludes the treatment of dementia, Alzheimers disease and Parkinsons disease. . Particularly preferred compounds include: (S)-(+)-2-[4-(2-fluorobenzyloxy)-benzylamino]-propanamide (S)-(+)-2-[4-(3-fluorobenzyloxy)-benzylamino]-propanamide 2-[4-(3-Fluorobenzyloxy)-benzylamino]-2-(2-fluoropheny1)-acetamide 2-[4-(2-Fluorobenzylthio)-benzylamino]-propanamide 2-(4-(2-Thienyloxy)-benzylamino)-propanamide.
